|
2019 Conference Publication Bortezomib induces immunogenic cell death in melanoma and enhances immune responses in vivoDaignault, S. M., Ju, R. J., Spoerri, L., Stehbens, S. J., Dolcetti, R. and Haass, N. K. (2019). Bortezomib induces immunogenic cell death in melanoma and enhances immune responses in vivo. 49th Annual Meeting of the European Society for Dermatological Research (ESDR), Bordeaux, France, 18-21 September, 2019. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.jid.2019.07.506 |
|
2019 Conference Publication Enforcing cellular stress promotes apoptotic and immunogenic responses in melanomaDaignault, S. M., Spoerri, L., Ju, R. J., Stehbens, S. J., Hill, D. S., Dolcetti, R. and Haass, N. (2019). Enforcing cellular stress promotes apoptotic and immunogenic responses in melanoma. 46th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF), Munich, Germany, 13-16 March 2019. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1111/exd.13859 |
|
2019 Conference Publication Bortezomib-induced immunogenic cell death enhances immune response in melanomaDaignault, S. M., Ju, R., Spoerri, L., Stehbens, S. J., Hill, D. S., Gabrielli, B., Dolcetti, R. and Haass, N. K. (2019). Bortezomib-induced immunogenic cell death enhances immune response in melanoma. Society for Investigative Dermatology (SID) Meeting, Chicago, IL United States, 8-11 May 2019. London, United Kingdom: Nature Publishing Group. doi: 10.1016/j.jid.2019.03.907 |
|
2018 Journal Article Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancerPacker, Leisl M., Stehbens, Samantha J., Bonazzi, Vanessa F., Gunter, Jennifer H., Ju, Robert J., Ward, Micheal, Gartside, Michael G., Byron, Sara A. and Pollock, Pamela M. (2018). Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer. Molecular Oncology, 13 (4), 738-756. doi: 10.1002/1878-0261.12422 |
|
2018 Journal Article The role of melanoma cell-stroma interaction in cell motility, invasion, and metastasisJu, Robert J., Stehbens, Samantha J. and Haass, Nikolas K. (2018). The role of melanoma cell-stroma interaction in cell motility, invasion, and metastasis. Frontiers in Medicine, 5 (NOV) 307, 1-9. doi: 10.3389/fmed.2018.00307 |
|
2018 Journal Article FGFR2b activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancerStehbens, Samantha J., Ju, Robert J., Adams, Mark N., Perry, Samuel, Haass, Nikolas K., Bryant, David M. and Pollock, Pamela M. (2018). FGFR2b activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer. Journal of Cell Science, 131 (15) jcs.213678, 1-16. doi: 10.1242/jcs.213678 |
|
2017 Journal Article PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2mutant endometrial cancersPacker, Leisl M., Geng, Xinyan, Bonazzi, Vanessa F., Ju, Robert J., Mahon, Clare E., Cummings, Margaret C., Stephenson, Sally-Anne and Pollock, Pamela M. (2017). PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2mutant endometrial cancers. Molecular Cancer Therapeutics, 16 (4), 637-648. doi: 10.1158/1535-7163.MCT-16-0415 |
|
2016 Conference Publication Combination of BGJ398 with either a pan-PI3K inhibitor or a specific PIK3CA inhibitor shows synergy in FGFR2 mutant endometrial cancer cell linesPacker, L., Geng, X., Bonazzi, V., Mahon, C., Ju, R., Stephenson, S. and Pollock, P. (2016). Combination of BGJ398 with either a pan-PI3K inhibitor or a specific PIK3CA inhibitor shows synergy in FGFR2 mutant endometrial cancer cell lines. 24th Biennial Congress of the European Association for Cancer Research, Manchester, United Kingdom, 9 – 12 July 2016. Oxford, United Kingdom: Elsevier. doi: 10.1016/s0959-8049(16)61523-x |
